Kornimate/medical-research-clean huggingface dataset:
asthma control among patients receiving inhaled corticosteroids in thailand

Conditions: Asthma

Summary: the purpose of this study is to determine the percentage of patients who has reached the gina guideline of asthma treatment after receiving any inhaled corticosteroid for 3 months or longer in actual clinical practice. such percentage for each level of severity - mild, moderate and severe persistent asthma as well as the differences of these rates will also be explored.


Eligibility criteria:
inclusion criteria: * established persistent asthma * currently treated with any inhaled corticosteroid therapy but not symbicort nor seretide for 3 months or longer exclusion criteria: * currently participating or have participated in a study with an investigational compound within the last 30 days * current diagnosis of chronic obstructive pulmonary disease (copd) * smoked more than 10 packs a year

Keywords: asthma inhaled corticosteroid thai patient eligibility persistent asthma
10 prescriptions an hour. group treatment and physical activity referral in a primary health care setting

Conditions: Type 2 Diabetes; Hypertension

Summary: the purpose of this study is to determine the effects of group treatment including physical activity referral (par) on level of physical activity and quality of life in patients diagnosed with type 2 diabetes and/or hypertension in a primary health care setting

a sedentary lifestyle and low levels of physical activity in populations are major health problems today and contribute substantially to poor health and diseases such as type 2 diabetes and hypertension. an increased and systematic effort to increase physical activity in the swedish population in general, and in patients with type 2 diabetes/hypertension in particular, is important. written prescriptions of physical activity with follow-up (i.e., par), is a cost-efficient way to increase physical activity in individuals. the aim of this trial is to study whether physical activity is increased by a group method involving pars in patients with hypertension and/or type 2 diabetes compared with a control group that receives usual care in the same primary care setting. follow-up will be performed at 6 and 12 months. this trial is being conducted to determine whether it is possible to offer pars to more patients in a way that requires less effort and resources. the intervention in this study requires 10 minutes of a health care worker's time per patient during a 6-month period. each patient requires 100 minutes with an instructor who oversees the group intervention. group treatment is given 3 weeks after baseline and at 6 months. follow-up at 12 months involves data collection, but no intervention. an empowerment process, with the 5-a-model as framework, will be used in the clinical intervention. all participants will be required to fill in questionnaires and wear an actigraph gtm1/gtm3 for 7 days at baseline and at 6 and 12 months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension or type 2 diabetes since 10-09-2009 at st hans primary health care center, lund, sweden exclusion criteria: * dementia * psychosis * drug abuse * mental retardation * inability to walk without assistance * inability to speak swedish

Keywords: group treatment physical activity referral type 2 diabetes hypertension
attentional bias in body dysmorphic disorder

Conditions: Body Dysmorphic Disorders

Summary: body dysmorphic disorder (bdd) participants will demonstrate greater attentional biases as compared to healthy control (hc) participants. greater attention bias will be associated with greater distress. greater attention bias will be associated with greater symptom severity.


Eligibility criteria:
inclusion criteria for bdd and healthy control participants: * males and females 18 years of age or older * sufficient fluency of english to understand study staff, procedures, and questionnaires * ability to provide informed consent inclusion for bdd participants only; * primary diagnosis of diagnostic and statistical manual 4th edition (dsm-iv-tr) bdd * bdd yale-brown obsessive compulsive disorder score (y-bocs) of \> 20 * primary facial/head concern exclusion criteria: * major medical or neurological conditions * schizophrenia, schizoaffective disorder, or any other current lifetime dsm-iv psychotic disorder that is not attributable to delusional bdd * current suicidality * current homicidality exclusion criteria for healthy controls: * any current axis i psychiatric illness * history of bdd

Keywords: bdd
real-world treatment patterns and outcomes among arcc patients on cabozantinib or axitinib in england

Conditions: Renal Cell Carcinoma

Summary: the present study will aim to describe and understand, in the real-world, the clinical characteristics, treatment patterns and outcomes of advanced renal cell carcinoma (arcc) patients treated with cabozantinib or axitinib monotherapy in england using the existing data source, cancer analysis system (cas).


Eligibility criteria:
inclusion criteria: * patients with initial renal cancer diagnosis * patients diagnosed at stage iii or stage iv (as defined in cas): as evidence for advanced/metastatic rcc * for patients with stage i/ii or patients with missing information on staging * patients who received sact1 treatment following initial renal cancer diagnosis through end of enrolment (31 july 2019) * patients who received cabozantinib or axitinib treatment exclusion criteria: * diagnosis of concomitant tumour apart from non-melanoma skin cancer in the three years prior to the diagnosis of arcc * less than 18 years of age at the time of initial arcc diagnosis * sact treatment more than 30 days prior to initial arcc diagnosis
assessment of weber humeral derotational osteotomy using ct scan

Conditions: Hill Sachs

Summary: subjects who have had the weber osteotomy for hill-sachs lesions will have ct of both shoulders. amount of rotation in operative shoulder will be compared to contralateral. qol will be assessed


Eligibility criteria:
inclusion criteria: * subjects who have had the weber osteotomy

Keywords: hill sachs weber osteotomy shoulder dislocation
a study on the intervention of metabolic syndrome patients with exercise prescription based on ventilatory threshold using cardiopulmonary exercise test

Conditions: Metabolic Syndrome X

Summary: analyze the clinical intervention effects and differences of progressive precision exercise prescriptions formulated by two methods for determining exercise intensity on metabolic syndrome (ms). compare the effects of the two on the cardiovascular endurance of the ms population and verify the effectiveness of individualized methods in reducing absolute exercise intensity for ms patients.


Eligibility criteria:
inclusion criteria: 1. patients were included who met the chinese diabetic society diagnostic criteria for ms-i.e., three or more of the following five items: (i) abdominal obesity (i.e., central obesity) with waist circumference ≥ 90 cm in males and ≥ 85 cm in females; (ii) hyperglycemia defined as fasting blood glucose ≥ 6.1 mmol/l or blood glucose ≥ 7.8 mmol/l two hours after glucose loading, or diagnosis of diabetes mellitus; (iii) hypertension defined as blood pressure ≥ 130/85 mmhg or diagnosed with hypertension; (iv) fasting triglycerides (tg) ≥ 1.70 mmol/l; and (v) fasting high-density lipoprotein cholesterol (hdl-c) \&lt; 1.04 mmol/l. 2. patients were aged 25 to 65 years, with no restrictions on number of males or females. 3. patients exhibited a long-term sedentary lifestyle and did not carry out moderate-intensity physical activity for at least three d/week of 30 min/d duration within three months of the study. 4. patients were willing to participate and sign the informed consent form. exclusion criteria: 1. patients in an acute phase of various diseases or with organ failure, tumor, myocardial infarction, cardiac insufficiency, myocarditis, or chronic lung disease; 2. patients with long-term alcohol consumption and those unable to ensure regular lifestyle habits during the intervention period; 3. patients who were unable to ensure that they would carry out the stipulated exercise protocol during the intervention; and 4. patients with drug modifications during the intervention that could affect the outcome markers.
thoracic spine thrust manipulation compared to sham manipulation in individuals with subacromial pain syndrome

Conditions: Subacromial Impingement; Subacromial Impingement Syndrome

Summary: this study evaluates the immediate and short-term effects of a supine upper thoracic spine thrust manipulation, seated upper thoracic spine thrust manipulation, and sham manipulation for individuals with subacromial pain syndrome. the participants were randomized to receive one of the three interventions and baseline measures for the dependent variables were repeated immediately after the delivery of the intervention.

thoracic spine thrust manipulation has been shown to be effective in reducing pain and improving function in individuals with subacromial pain syndrome (subacromial impingement). it remains unknown if individuals respond differently to different manipulation techniques. this study examines the immediate effects on pain and short-term effects on pain and function using the penn shoulder score (pss) as well as the immediate effects on scapular kinematics (upward rotation and posterior tilt, specifically), pectoralis minor muscle length, and scapulothoracic muscle force production for the middle trapezius, lower trapezius, and serratus anterior.

Eligibility criteria:
inclusion criteria: * currently experiencing shoulder pain for less than 6 months * at least 3 of the following findings: 1) pain localized to the proximal anterolateral shoulder region, 2) positive neer or hawkins-kennedy impingement test, 3) pain with active shoulder elevation (which may include a painful arc), 4) active shoulder abduction rom of at least 90°, 5) passive shoulder external rotation rom of at least 45°, and 6) pain with isometric resisted abduction or external rotation exclusion criteria: * signs of a complete rotator cuff tear * significant loss of glenohumeral motion * acute inflammation * cervical spine-related symptoms including a primary complaint of neck pain, signs of central nervous system or cervical nerve root involvement, or reproduction of shoulder or arm pain with cervical rotation, axial compression, or spurling test * previous neck or shoulder surgery * positive apprehension test or relocation test * history of shoulder fracture or dislocation * history of nerve injury affecting upper extremity function * any contraindication for thrust manipulation to the thoracic spine including osteoporosis, fracture, malignancy, systemic arthritis, or infection * fear or unwillingness to undergo thoracic spine manipulation

Keywords: scapular kinematics thoracic spine thrust manipulation
study of 18f-florastamin pet/ct imaging in patients with at least intermediate risk prostate cancer

Conditions: Prostate Cancer

Summary: in this study, 18f-florastamin pet/ct will be performed in patients with at least intermediate risk prostate cancer, to assess the diagnostic performance and safety of 18f-florastamin pet/ct imaging. this study will first carry out the pilot study (including pharmacokinetics and radiation dosimetry).


Eligibility criteria:
inclusion criteria: 1. subjects fully understood the content, process, and potential risks of the study and voluntarily signed an informed consent form (icf). 2. male subjects aged 18 or older. 3. subjects with histopathological diagnosis of prostate adenocarcinoma. 4. according to clinical judgment, radical prostatectomy and pelvic lymph node dissection (which can include patients with localized, regional lymph node metastasis or oligometastatic prostate cancer) are planned, and there is no surgical contraindication. 5. if it is localized prostate cancer, according to the prostate cancer diagnosis and treatment guidelines of 2021 chinese society of clinical oncology, it is necessary to meet any of the following criteria: intermediate risk: has at least one intermediate risk factor: t2b-t2c; gleason pattern 2 or 3; psa 10-20 ng/ml, and does not include feature of high-risk or very-high-risk groups. high risk: has no very-high-risk features and has at least one high-risk feature: t3a; gleason grade group 4 or 5; psa \>20 ng/ml. very high risk: has at least one of the following: t3b-t4; primary gleason pattern 5; more than 4 punctures with gleason grade group 4 or 5. 6. ecog score 0 or 1. 7. subjects who meet the following conditions in hematology, renal function, and liver function: * platelet count\>100 \* 10\^9/l * urea nitrogen and creatinine\<1.5 times upper limits of normal * ast and alt\<2.5 times upper limits of normal. 8. expected survival time ≥ 6 months. 9. subjects and their partners must use effective contraceptive measurements and avoid sperm donation from the date of signing icf to 3 months after administration. exclusion criteria: 1. subjects who have participated in other interventional clinical trials before signing icf and were within the 5 half-lives of the investigational drug, or who are currently participating in other interventional clinical trials or have participated in clinical trials of radioactive drugs within 1 year before signing icf and have been discontinued for less than 3 months until the signing date of icf. 2. intravenous injection of iodinated contrast medium within 24 hours, or any high-density oral contrast medium (such as barium sulfate. oral water contrast is acceptable, such as compound meglumine diatrizoate oral liquid) within 5 days, prior to study drug administration. 3. subjects administered any high energy (\>300 kev) gamma-emitting radioisotope within five physical half-lives prior to study drug administration. 4. patients with prior androgen deprivation therapy or any other neoadjuvant agent. 5. the investigator determines that there are any medical diseases or other conditions that affect the safety or compliance of the subjects.
improving hypertension detection and control through a hypertension certification program based upon the hypertension canada guidelines

Conditions: Hypertension

Summary: this study will assess the impact of a hypertension management certification program for community pharmacists on the blood pressure control of patients managed by the pharmacists enrolled. the investigators will compare the systolic blood pressure of patients identified to have hypertension in the community that are followed by pharmacists who have undergone the certification course, and compare their blood pressure outcomes to subjects managed by pharmacists who have not yet received the training.

hypertension canada proposes the first "hypertension canada professional certification program"(hc-pcp), specifically designed for alberta pharmacists, to provide care and support to those at risk for or living with hypertension. through this program, the investigators hope to help with prevention of the costly and chronic conditions to which hypertension often leads, like kidney failure, stroke, and heart disease. the hc-pcp aims to provide training to pharmacists in the screening, prevention, and management of hypertension. it has been identified that the development and implementation of this certification program provides a unique opportunity to evaluate the impact of such a program on blood pressure reduction. the investigators are aiming to assess the impact of pharmacist management on blood pressure control in patients with hypertension. the development of the hc-pcp and the evaluation of its impact will occur in 2 phases. phase 1 involves the development and implementation of the educational portion of the certification program. phase 2 involves conducting a 1 year long study to assess the impact of the hc-pcp on blood pressure in patients with poorly controlled hypertension. this will be launched in pharmacies in alberta.

Eligibility criteria:
inclusion criteria: * patients with poorly controlled blood pressure (\>140/90mmhg or \>130/80mmhg if they have diabetes). exclusion criteria: * unwilling to sign the consent form. * unwilling to participate in follow up visits. * current hypertension urgency or emergency (sbp \> 180mmhg or dbp \> 120mmhg).
clinical trial of zocor (simvastatin) and vytorin (ezetimibe/simvastatin) in adolescents with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus; Dyslipidemia

Summary: the purpose of the study is to establish the safety of ezetimibe/simvastatin and simvastatin in adolescents with type 1 diabetes and to determine the amount of decrease in ldl-cholesterol.the study hypothesizes that simvastatin and ezetimibe/simvastatin will be safe in adolescents with type 1 diabetes and will lower ldl-cholesterol at 6 months.

cardiovascular disease is the leading cause of death in people with type 1 diabetes mellitus (t1dm) and since atherosclerosis begins in childhood, data to inform clinicians as to appropriate dyslipidemia treatment in this high-risk population are of great public health importance. in this trial of lipid-lowering medications (zocor \[simvastatin\], a statin, compared to vytorin \[ezetimibe/simvastatin\], a combination of a statin and zetia, a medication that blocks cholesterol absorption) will be performed in patients ages 12-18 years with ldl ≥ 130 mg/dl, consistent with current ada guidelines. the study hypothesizes that zocor and vytorin will be safe in adolescents with t1dm and will lower ldl-cholesterol at 6 months compared to baseline. in a two-arm design, vytorin will lower ldl-c more than monotherapy with zocor.

Eligibility criteria:
inclusion criteria: * 12-18 years of age with type 1 diabetes and seen at the barbara davis center for childhood diabetes * positive diabetes auto-antibodies or provider diagnosed type 1 diabetes * ldl \> 130 mg/dl. exclusion criteria: * familial hypercholesterolemia, triglycerides (tg) \> 400mg/dl * type 1 diabetes of less than three-month duration * hba1c\>9.5% * abnormal thyroid function * abnormal creatine kinase (ck) values (defined as \> 10 times the upper limit of normal) * abnormal liver function tests (alt/ast) (defined as \>3 times the upper limit of normal) * pregnancy, and patients on oral contraceptives * all resources are in english. spanish speakers will not be available for the follow-up calls.

Keywords: type 1 diabetes mellitus dyslipidemia adolescents
effect of progressive loading protocol on bone mineral density

Conditions: Osteoporosis

Summary: the aims of this study are to examine the effects of progressive loading exercises protocol on bone mineral density in osteoporotic patient's well-being and quality of life before a fracture occurs in order to create remedies. in addition, the available data from health research and clinical studies on osteoporosis will be evaluated for their impact on patient well-being and quality of life, providing an up-to-date and comprehensive overview of evidence-based treatments.

progressive loading protocol (plp): the subjects in the progressive loading group will undergo 4-7 days of moderate to high impact loading activities per week for the duration of 6 weeks. the plp is adapted and modified based on exercise and sports science australia (essa) position statement on exercise prescription for the prevention and management of osteoporosis. the participants in the progressive loading group will perform vertical and multidirectional jumping, bounding, hopping, skipping rope, drop jumps and bench stepping. the weight bearing intensity will be progressed by increasing heights for activities such as bounding and drop jumping, adding weighted vests and changing directions. to prevent the risk of injury, the participants would be instructed to avoid the loaded spine flexion or twisting movements of the spine. frail individuals should be supervised and exercised within reach of a railing or other stable support. intensity: moderate-to-high weight bearing impact loads (\>2 times body weight) that are progressive, novel, and multidirectional, within the limits of pain, increasing as tolerated. frequency: 4-7 days per week sets/repetitions: aim to work up to 50 repetitions over time (5 sets of 10 repetitions with 1-2 min rest between sets) the subjects in the control group will undergo twelve weeks of low impact aerobics training along with a health awareness program..

Eligibility criteria:
inclusion criteria: * subject with history of diabetes, hypertension exclusion criteria: * subject with history of kidney diseases, cardiopulmonary diseases, thrombosis, hyperprolactinemia, spondylolisthesis, back/leg deformities or surgeries, osteoarthritis, pacemakers, implants of the lower extremity and spine, tumors, migraines, or having any other diseases that affect bone metabolism or neuromuscular performance.

Keywords: quality of life bone mineral
decision making in end of life as individual preferences

Conditions: Terminal Diseases

Summary: it is not universal that terminally ill patients choose surrogate in the event of disagreement between the treating physician and the surrogate at the end of their lives. there are several factors that influence the terminally ill patient's decision to choose a decision maker at the end of his / life.

the right of the patient to exercise autonomy, whether to accept the recommendation of physician is not lost when the patient is unable to make health related decision. this is the basis of substituted judgment. without written advance directives, a surrogate has to be assigned using relevant state relationship hierarchy, and usually a family member serves as a surrogate when the patient no longer has capacity to make medical decisions. several studies showed that surrogates do not predict the patients preference accurately when both are asked to respond to hypothetical questions. patient designated hierarchy predicted the patient treatment preferences with 69% accuracy whereas legally assigned proxy was accurate in 68%. even the prior discussion of the treatment preferences did not seem to improve the surrogate accuracy. surrogates make errors predicting patient's preferences in different directions, as was found in several studies. three studies have found that surrogates err by providing intervention that patients do not want, while others found no specific trends. other studies showed physicians to be less accurate than surrogates in predicting the patient's wishes. some studies have shown that patients want their surrogates to make decision for them when there is disagreement between the patient's wishes and his or her surrogate. no studies have looked at patients preferences when there is conflict between the surrogate and the physician. to choose the right surrogate is a paramount. one way to do this is to analyze the patient's trends as to 'how' and 'why' patients choose his or her surrogates. little is known about what factors influence the patients' decisions to choose the surrogate and what would be their decision in the event of disagreement between the treating physician and the surrogate. factors such as patient's culture, ethnic or religious background may play an important role in patients' preferences at the end of their lives. the investigators aim to assess terminally ill patients' decision making preferences at the end of life and identify specific factors that determine their preferences.

Eligibility criteria:
inclusion criteria: 1. non-resectable malignancy undergoing palliative care treatment 2. severe end stage copd with fev1 \ six months 3. end stage cardiomyopathy nyha class iii/iv, not candidate for heart transplantation. exclusion criteria: * none

Keywords: questionnaire